Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 2/20 | 0.81 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.81 |
| ▸ | SMO | Q99835 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | PTGES | O14684 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | F2R | P25116 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2010680 | 0.98 | KCNK3 (0.78) | KCNK3KCNK9SMOMAPTPTGES | |
| Ether SCHEMBL2011650 | 0.90 | KCNK3 (0.66) | KCNK3KCNK9SMOMAPTPTGES | |
| SCHEMBL2005896 | 0.88 | KCNK3 (0.76) | KCNK3KCNK9SMOMAPTPTGES | |
| SCHEMBL2058337 | 0.86 | ALDH1A1 (0.71) | KCNK3KCNK9NPC1LMNARAB9A | |
| Hydrochloric Acid SCHEMBL2105080 | 0.84 | MEN1 (0.64) | KCNK3KCNK9MAPTNPC1LMNA | |
| SCHEMBL1813249 | 0.84 | RAB9A (0.81) | KCNK3KCNK9MAPTPTGESNPC1 | |
| SCHEMBL1203522 | 0.84 | SMO (0.80) | KCNK3KCNK9SMOMAPTNPC1 | |
| SCHEMBL19491387 | 0.83 | KCNK3 (0.78) | KCNK3KCNK9SMOMAPTNPC1 | |
| Hydrochloric Acid SCHEMBL2103616 | 0.83 | NPC1 (0.61) | KCNK3KCNK9NPC1LMNARAB9A | |
| SCHEMBL15778718 | 0.83 | FADS1 (0.74) | KCNK3KCNK9SMOMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12310944-B2 | Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and use thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2025-05-27 | — | — | US | disclosed |
| US-20230165833-A1 | Selective Butyrylcholinesterase Inhibitor or Pharmaceutically Acceptable Salt Thereof, Preparation Method and Use Thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2023-06-01 | — | — | US | disclosed |
| WO-2021042410-A1 | SELECTIVE BUTYRYLCHOLINESTERASE INHIBITOR OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 中国药科大学 | 2021-03-11 | — | — | WO | disclosed |
| CN-110627767-B | Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and application thereof | 中国药科大学 | 2020-08-25 | — | — | CN | disclosed |
| EP-2535327-A1 | Insecticidal 3-acylaminobenzanilides | Bayer CropScience AG (DE) | 2012-12-19 | — | — | EP | disclosed |
| EP-2535327-A1 | Insecticidal 3-acylaminobenzanilides | Bayer CropScience AG (DE) | 2012-12-19 | — | — | EP | disclosed |
| US-8207219-B2 | Ion channel modulating activity I | CARDIOME PHARMA CORP. (CA) | 2012-06-26 | — | — | US | disclosed |
| US-20120095073-A1 | ION CHANNEL MODULATING ACTIVITY II | CARDIOME PHARMA CORP. (CA) | 2012-04-19 | — | — | US | disclosed |
| CN-102177135-A | Acylaminobenzamide derivatives | BAYER CROPSCIENCE AG | 2011-09-07 | — | — | CN | disclosed |
| US-20110201603-A1 | Novel Acylaminobenzamide Derivatives | BAYER CROPSCIENCE AG (DE) | 2011-08-18 | — | — | US | disclosed |
| WO-2005018635-A2 | ION CHANNEL MODULATING ACTIVITY I | CARDIOME PHARMA CORP. (CA) | 2005-03-03 | — | — | WO | disclosed |
| US-20030186998-A1 | Methods for treatment of disorders of cardiac contractility | JOHN HOPKINS UNIVERSITY | 2003-10-02 | — | — | US | disclosed |
| US-6569862-B1 | Adminstering xanthine oxidase inhibitor such as allopurinol | JOHNS HOPKINS UNIVERSITY | 2003-05-27 | — | — | US | disclosed |
| EP-1044002-A4 | METHODS FOR TREATMENT OF DISORDERS OF CARDIAC CONTRACTILITY | UNIV JOHNS HOPKINS (US) | 2003-05-02 | — | — | EP | disclosed |
| US-6191136-B1 | ADMINISTERING XANTHINE OXIDASE INHIBITOR | JOHNS HOPKINS UNIVERSITY | 2001-02-20 | — | — | US | disclosed |
| EP-1044002-A1 | METHODS FOR TREATMENT OF DISORDERS OF CARDIAC CONTRACTILITY | JOHNS HOPKINS UNIVERSITY (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999024038-A1 | METHODS FOR TREATMENT OF DISORDERS OF CARDIAC CONTRACTILITY | JOHNS HOPKINS UNIVERSITY (US) | 1999-05-20 | — | — | WO | disclosed |
| US-5674887-A | Prevention of bone resorption | ELI LILLY AND COMPANY (US) | 1997-10-07 | — | — | US | disclosed |
| US-5436258-A | Prevention of bone resorption | ELI LILLY AND COMPANY (US) | 1995-07-25 | — | — | US | disclosed |
| EP-0587378-A1 | Prevention of bone resorption | ELI LILLY AND COMPANY (US) | 1994-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186998-A1 | Methods for treatment of disorders of cardiac contractility | TNNI3, TNNT2, RYR2 | KCNK3 745/4885KCNK9 1465/4885SMO 3822/4885 |
| US-20110201603-A1 | Novel Acylaminobenzamide Derivatives | KCNB1, KCNA5, KCNA7 | KCNK3 174/4885KCNK9 461/4885SMO 4590/4885 |
| US-20230165833-A1 | Selective Butyrylcholinesterase Inhibitor or Pharmaceutically Acceptable Salt Thereof, Preparation Method and Use Thereof | BCHE, ACHE, BACE1 | KCNK3 1980/4885KCNK9 545/4885SMO 2084/4885 |
| US-12310944-B2 | Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and use thereof | BCHE, ACHE, BACE1 | KCNK3 2135/4885KCNK9 679/4885SMO 2236/4885 |
| US-20120095073-A1 | ION CHANNEL MODULATING ACTIVITY II | KCNH1, KCNN3, KCNJ2 | KCNK3 77/4885KCNK9 83/4885SMO 4600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.